Nura Bio

Nura Bio is a clinical-stage biopharmaceutical company developing neuroprotective therapies for the treatment of various neurological disorders. Nura Bio's small molecule research and early development pipeline spans from Phase 1 discovery to Phase 1. Nura Bio focuses on developing therapies that prevent axonal degeneration and/or modulate microglial responses to degeneration and injury, aiming to confer neuroprotection in diseases of the central, peripheral, and ocular nervous systems. NB-4746 is the lead asset in Nura Bio’s small molecule portfolio. NB-4746 targets SARM1, a neuron-enriched NAD hydrolase that has emerged as a key intrinsic metabolic sensor in axons and a central driver of axonal degeneration.